$CTXR
Citius Pharmaceuticals, Inc. Stock $ctxr

$ctxr Overview Financials Valuation SEC Filings Company Website

2025 Q1 Form 10-Q Financial Statement

#000121390025014321 Filed on February 14, 2025

Income Statement

Concept	2025 Q1	2024 Q4	2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development		$2.127M
YoY Change		-18.87%
% of Gross Profit
Depreciation & Amortization		$0.00
YoY Change		-100.0%
% of Gross Profit
Operating Expenses		$10.04M
YoY Change		7.48%
Operating Profit		-$10.04M
YoY Change		7.48%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net		$22.61K
YoY Change		-91.09%
Pretax Income		-$10.02M
YoY Change		10.23%
Income Tax		$264.2K
% Of Pretax Income
Net Earnings		-$10.28M
YoY Change		11.38%
Net Earnings / Revenue
Basic Earnings Per Share		-$1.30
Diluted Earnings Per Share		-$1.30
COMMON SHARES
Basic Shares Outstanding	8.593M shares	7.727M shares	180.7M shares
Diluted Shares Outstanding		7.492M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$1.100M	$3.252M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory	$14.38M	$8.269M
Prepaid Expenses	$2.846M	$2.700M
Receivables
Other Receivables
Total Short-Term Assets	$18.33M	$14.22M
YoY Change	-35.03%	-58.63%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill	$9.347M	$9.347M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$102.2M	$102.2M
YoY Change	268383.6%	268383.6%
Total Long-Term Assets	$102.4M	$102.4M
YoY Change	47.96%	47.93%
TOTAL ASSETS
Total Short-Term Assets	$18.33M	$14.22M
Total Long-Term Assets	$102.4M	$102.4M
Total Assets	$120.7M	$116.7M
YoY Change	23.93%	12.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.364M	$4.927M
YoY Change	178.18%	68.32%
Accrued Expenses	$6.242M	$17.03K
YoY Change	2154.33%	-96.43%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$44.81M	$35.81M
YoY Change	703.14%	519.74%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$44.81M	$35.81M
Total Long-Term Liabilities
Total Liabilities	$51.78M	$42.55M
YoY Change	329.2%	249.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$211.1M	-$201.4M
YoY Change	23.14%	24.13%
Common Stock	$7.727K	$7.247K
YoY Change	-95.14%	-95.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$65.41M	$70.08M
YoY Change
Total Liabilities & Shareholders Equity	$120.7M	$116.7M
YoY Change	23.93%	12.59%

Cashflow Statement

Concept	2025 Q1	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$10.28M
YoY Change		11.38%
Depreciation, Depletion And Amortization		$0.00
YoY Change		-100.0%
Cash From Operating Activities		-$4.726M
YoY Change		-22.97%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		$2.574M
YoY Change
NET CHANGE
Cash From Operating Activities		-$4.726M
Cash From Investing Activities
Cash From Financing Activities		$2.574M
Net Change In Cash		-$2.152M
YoY Change		-64.93%
FREE CASH FLOW
Cash From Operating Activities		-$4.726M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024Q4	dei	Document Type DocumentType	10-Q
CY2024Q4	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q4	dei	Document Period End Date DocumentPeriodEndDate	2024-12-31
CY2024Q4	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q4	dei	Entity File Number EntityFileNumber	001-38174
CY2024Q4	dei	Entity Registrant Name EntityRegistrantName	Citius Pharmaceuticals, Inc.
CY2024Q4	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2024Q4	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-3425913
CY2024Q4	dei	Entity Address Address Line1 EntityAddressAddressLine1	11 Commerce Drive
CY2024Q4	dei	Entity Address Address Line2 EntityAddressAddressLine2	First Floor
CY2024Q4	dei	Entity Address City Or Town EntityAddressCityOrTown	Cranford
CY2024Q4	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2024Q4	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07016
CY2024Q4	dei	City Area Code CityAreaCode	(908)
CY2024Q4	dei	Local Phone Number LocalPhoneNumber	967-6677
CY2024Q4	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
CY2024Q4	dei	Trading Symbol TradingSymbol	CTXR
CY2024Q4	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q4	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q4	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q4	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q4	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q4	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q4	dei	Entity Shell Company EntityShellCompany	false
CY2025Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8593433	shares
CY2024Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1100079	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3251880	usd
CY2024Q4	us-gaap	Inventory Net InventoryNet	14381369	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	8268766	usd
CY2024Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2845739	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2700000	usd
CY2024Q4	us-gaap	Assets Current AssetsCurrent	18327187	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	14220646	usd
CY2024Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	191412	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	246247	usd
CY2024Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	38062	usd
CY2024Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	38062	usd
CY2024Q4	ctxr	In Process Research And Development InProcessResearchAndDevelopment	92800000	usd
CY2024Q3	ctxr	In Process Research And Development InProcessResearchAndDevelopment	92800000	usd
CY2024Q4	us-gaap	Goodwill Goodwill	9346796	usd
CY2024Q3	us-gaap	Goodwill Goodwill	9346796	usd
CY2024Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	102184858	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	102184858	usd
CY2024Q4	us-gaap	Assets Assets	120703457	usd
CY2024Q3	us-gaap	Assets Assets	116651751	usd
CY2024Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7364120	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4927211	usd
CY2024Q4	ctxr	License Payable LicensePayable	28400000	usd
CY2024Q3	ctxr	License Payable LicensePayable	28400000	usd
CY2024Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6242178	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17027	usd
CY2024Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2595091	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2229018	usd
CY2024Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	204569	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	241547	usd
CY2024Q4	us-gaap	Liabilities Current LiabilitiesCurrent	44805958	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	35814803	usd
CY2024Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6978040	usd
CY2024Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6713800	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21318	usd
CY2024Q4	us-gaap	Liabilities Liabilities	51783998	usd
CY2024Q3	us-gaap	Liabilities Liabilities	42549921	usd
CY2024Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	16000000	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	16000000	shares
CY2024Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7727243	shares
CY2024Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7727243	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7247243	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7247243	shares
CY2024Q4	us-gaap	Common Stock Value CommonStockValue	7727	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	7247	usd
CY2024Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	276538816	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	271440421	usd
CY2024Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-211138464	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-201370218	usd
CY2024Q4	us-gaap	Stockholders Equity StockholdersEquity	65408079	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	70077450	usd
CY2024Q4	us-gaap	Minority Interest MinorityInterest	3511380	usd
CY2024Q3	us-gaap	Minority Interest MinorityInterest	4024380	usd
CY2024Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	68919459	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	74101830	usd
CY2024Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	120703457	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	116651751	usd
CY2024Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2127038	usd
CY2023Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2621910	usd
CY2024Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5387752	usd
CY2023Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3660728	usd
CY2024Q4	us-gaap	Share Based Compensation ShareBasedCompensation	2524824	usd
CY2023Q4	us-gaap	Share Based Compensation ShareBasedCompensation	3058185	usd
CY2024Q4	us-gaap	Operating Expenses OperatingExpenses	10039614	usd
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	9340823	usd
CY2024Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-10039614	usd
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-9340823	usd
CY2024Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	22608	usd
CY2023Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	253638	usd
CY2024Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	22608	usd
CY2023Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	253638	usd
CY2024Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10017006	usd
CY2023Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9087185	usd
CY2024Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	264240	usd
CY2023Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	144000	usd
CY2024Q4	us-gaap	Profit Loss ProfitLoss	-10281246	usd
CY2023Q4	us-gaap	Profit Loss ProfitLoss	-9231185	usd
CY2024Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-513000	usd
CY2024Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9768246	usd
CY2023Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9231185	usd
CY2024Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.3
CY2024Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.3
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.45
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.45
CY2024Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7492460	shares
CY2024Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7492460	shares
CY2023Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6358237	shares
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6358237	shares
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	74101830	usd
CY2024Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2574051	usd
CY2024Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2524824	usd
CY2024Q4	us-gaap	Profit Loss ProfitLoss	-10281246	usd
CY2024Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	68919459	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	91431488	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	76146	usd
CY2023Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3058185	usd
CY2023Q4	us-gaap	Profit Loss ProfitLoss	-9231185	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	85334634	usd
CY2024Q4	us-gaap	Profit Loss ProfitLoss	-10281246	usd
CY2023Q4	us-gaap	Profit Loss ProfitLoss	-9231185	usd
CY2024Q4	us-gaap	Share Based Compensation ShareBasedCompensation	2524824	usd
CY2023Q4	us-gaap	Share Based Compensation ShareBasedCompensation	3058185	usd
CY2023Q4	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	76146	usd
CY2024Q4	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	54835	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	50430	usd
CY2023Q4	us-gaap	Depreciation Depreciation	578	usd
CY2024Q4	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	264240	usd
CY2023Q4	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	144000	usd
CY2024Q4	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6112603	usd
CY2024Q4	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	145739	usd
CY2023Q4	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-25010	usd
CY2024Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2436909	usd
CY2023Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-280083	usd
CY2024Q4	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6225151	usd
CY2023Q4	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-199403	usd
CY2024Q4	ctxr	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	366073	usd
CY2023Q4	ctxr	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	273688	usd
CY2024Q4	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-58296	usd
CY2023Q4	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-52676	usd
CY2024Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4725852	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6135310	usd
CY2024Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	2574051	usd
CY2024Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2574051	usd
CY2024Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2151801	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-6135310	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3251880	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26480928	usd
CY2024Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1100079	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20345618	usd
CY2024Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4725852	usd
CY2024Q4	ctxr	Working Capital WorkingCapital	-26500000	usd
CY2023Q4	us-gaap	Management Fee Expense ManagementFeeExpense	90000	usd
CY2024Q4	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	1100000	usd
CY2024Q4	us-gaap	Commercial Paper CommercialPaper	300000000	usd
CY2024Q4	ctxr	Royalty Rate RoyaltyRate	0.15	pure
CY2024Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6134895	usd
CY2024Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	8246474	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6134895	usd
CY2024Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	2133862	usd
CY2024Q4	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	145739	usd
CY2024Q4	us-gaap	Payments For Advance To Affiliate PaymentsForAdvanceToAffiliate	2700000	usd
CY2024Q4	ctxr	Bid Price BidPrice	1
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	656084	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	36.41
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M3D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	185000	shares
CY2024Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.5
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	841084	shares
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.49
CY2024Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M17D
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	502184	shares
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	40.62
CY2024Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y6M25D
CY2024Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.15
CY2024Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P36M
CY2024Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2524824	usd
CY2023Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3058185	usd
CY2024Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3458937	shares
CY2024Q4	us-gaap	Operating Lease Cost OperatingLeaseCost	59705	usd
CY2023Q4	us-gaap	Operating Lease Cost OperatingLeaseCost	59705	usd
CY2024Q4	us-gaap	Variable Lease Cost VariableLeaseCost	1264	usd
CY2023Q4	us-gaap	Variable Lease Cost VariableLeaseCost	1204	usd
CY2024Q4	us-gaap	Lease Cost LeaseCost	60969	usd
CY2023Q4	us-gaap	Lease Cost LeaseCost	60909	usd
CY2024Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M18D
CY2024Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	190716	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	21460	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	212176	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7607	usd
CY2024Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	204569	usd
CY2024Q4	ctxr	Lease Asset LeaseAsset	191412	usd
CY2024Q3	ctxr	Lease Asset LeaseAsset	246247	usd
CY2024Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	191412	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	246247	usd
CY2024Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	204569	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	241547	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21318	usd
CY2024Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	204569	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	262865	usd
CY2024Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	4870	usd
CY2023Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	9275	usd
CY2024Q4	us-gaap	Payments For Fees PaymentsForFees	250000	usd
CY2024Q4	us-gaap	Production And Distribution Costs ProductionAndDistributionCosts	17300000	usd
CY2024Q4	ctxr	Agreements Amount AgreementsAmount	4500000	usd
CY2024Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1
CY2024Q4	ctxr	Salesof Common Shares SalesofCommonShares	122650	shares
CY2024Q4	ctxr	Salesof Common Shares Gross Proceeds SalesofCommonSharesGrossProceeds	503793	usd
CY2024Q4	ctxr	Sales Of Common Shares Net Proceeds SalesOfCommonSharesNetProceeds	487050	usd
CY2024Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.91
CY2024Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2024Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024Q4	us-gaap	Revenues Revenues		usd
CY2023Q4	us-gaap	Revenues Revenues		usd
CY2023Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2024Q4	ctxr	Net Loss Attributable To Noncontrolling Interest NetLossAttributableToNoncontrollingInterest		usd
CY2024Q4	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2024Q4	us-gaap	Depreciation Depreciation		usd
CY2023Q4	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2023Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2024Q3	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	270000	usd
CY2024Q4	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2024Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2024Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2024Q4	dei	Entity Central Index Key EntityCentralIndexKey	0001506251
CY2024Q4	dei	Amendment Flag AmendmentFlag	false
CY2024Q4	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2025
CY2024Q4	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q4	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30

Files In Submission

Name	View Source	Status
0001213900-25-014321-index-headers.html	Edgar Link	pending
0001213900-25-014321-index.html	Edgar Link	pending
0001213900-25-014321.txt	Edgar Link	pending
0001213900-25-014321-xbrl.zip	Edgar Link	pending
ctxr-20241231.xsd	Edgar Link	pending
ea0230774-10q_citius.htm	Edgar Link	pending
ea023077401ex31-1_citius.htm	Edgar Link	pending
ea023077401ex31-2_citius.htm	Edgar Link	pending
ea023077401ex32-1_citius.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
ctxr-20241231_def.xml	Edgar Link	unprocessable
ctxr-20241231_lab.xml	Edgar Link	unprocessable
ctxr-20241231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ctxr-20241231_cal.xml	Edgar Link	unprocessable
ea0230774-10q_citius_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTXR
Citius Pharmaceuticals, Inc. Stock $ctxr

2025 Q1 Form 10-Q Financial Statement

#000121390025014321 Filed on February 14, 2025

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTXR Citius Pharmaceuticals, Inc. Stock $ctxr

2025 Q1 Form 10-Q Financial Statement

#000121390025014321 Filed on February 14, 2025

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTXR
Citius Pharmaceuticals, Inc. Stock $ctxr